Brean Murray Carret

Brean Murray Carret lowers its price target from $48 to $45 on Buy-rated Arrow Electronics (NYSE: ARW) as the company's March quarter results and guidance came in softer than anticipated. Brean Murray Carret notes, "Softer Mar Q EPS and Jun Q guide although revenue for each were in‐line – softer...

According to a research report published earlier today, Brean Murray Carret has increased Bally Technologies' (NYSE: BYI) PT from $53 to $56. In the report, Brean Murray Carret said, "Bally's F3Q supports our view that the company is experiencing momentum in its three business segments. Revenue...

According to a research report published this morning, Brean Murray Carret has lowered InterMune's (NASDAQ: ITMN) PT from $37 to $33. In the report, Brean Murray Carret said, "Topline Esbriet sales came in short of dampened expectations, with $4.9 million in net sales. We expect the top‐line miss...

According to a research report published this morning, Brean Murray Carret has decreased Baidu.com's (NASDAQ: BIDU) PT from $200 to $194. In the report, Brean Murray Carret commented, "We believe Baidu's growth story is largely intact in 2012 with SME starting robustly, while big advertisers'...

According to a research report published this morning, Brean Murray Carret has decreased Watts Water Technologies' (NYSE: WTS) PT from $48 to $45. In the report, Brean Murray Carret said, "Watts pre‐announcement of 1Q12 results was disappointing and raises some concerns. In the release, the...

Brean Murray Carret reiterates its Buy rating and $10 price target on Xerox (NYSE: XRX) following solid quarterly results across the board. Brean Murray Carret comments, "We were pleased to see Xerox broadly deliver solid operational results relative to our expectations (see Figure 1) and issue...

Brean Murray Carret lowers its price target from $48 to $43 on Buy-rated Peabody Energy (NYSE: BTU) as the company scales back US sales. Brean Murray Carret says, "Peabody lowered U.S. sales guidance by 10 million tons and now expects U.S. production of 185‐195 million tons. Importantly,...

Brean Murray Carret increases its rating from Hold to Buy on Rex Energy (NASDAQ: REXX) given asset sales, hedges and drilling catalysts. Price target is maintained at $14. Brean Murray Carret comments, "We are upgrading Rex Energy (REXX) to Buy from Hold with a $14 price target, equal to 85% of...

Brean Murray Carret raises its rating on New Jersey Resources (NYSE: NJR) from Hold to Buy and establishes a $49 price target based on recent share pullback presenting an opportunity to scale the position. Brean Murray Carret notes, "We've waited patiently to revisit our rating on the shares of...

Brean Murray Carret increases its price target from $20 to $22 on Buy-rated Electronics for Imaging (NASDAQ: EFII) on material potential EPS acceleration in the second half of the year. Brean Murray Carret says, "Reiterating EFI (Buy) as a Long‐Term Focus List pick [along with Dell (DELL $16.16,...

According to a research report published earlier today, Brean Murray Carret has increased Seagate Technology's (NYSE: STX) PT from $35 to $38. In the report, Sterne Agee commented, “We're raising our target price to $38 from $35, and our CY12 EPS to $11.90 from $11.25, and we see ongoing upside...

Brean Murray Carret initiates its coverage on SunCoke Energy (NYSE: SXC) with a Hold rating and a fair value estimate of $15, reflecting limited upside to valuation on capacity constraints. Brean Murray Carret comments, "While we have a favorable view of the domestic coke market, we believe that...

Brean Murray Carret initiates Whiting Petroleum Corporation (NYSE: WLL) with a Buy rating and a price target of $70 as the company shifts its development capex to Bakken de-risking. Brean Murray Carret says, "By concentrating 2012 drilling activity in de‐risked areas within Pronghorn/Lewis and...

According to a research report published earlier today, Brean Murray Carret has downgraded ViroPharma (NASDAQ: VPHM) from Buy to Hold, and removed its $37 PT. Brean Murray Carret commented in the report, “We expect that the approval of generic versions of Vancocin will result in a significant loss...

Following the news this morning that ViroPharma (NASDAQ: VPHM) was denied its U.S. Food and Drug Administration (FDA) citizen petition today, the global biotechnology company has been downgraded more than once. After the announcement that its top-selling drug, Vancocin, would not be receiving...